2025-12-25 - Analysis Report
Okay, here's a comprehensive analysis of Johnson & Johnson (JNJ) based on the data you provided.

**1) Return Rate Comparison & Alpha/Beta Analysis**

*   **Company Overview:** Johnson & Johnson is a multinational corporation that develops and manufactures pharmaceuticals, medical devices, and consumer packaged goods.
*   **Cumulative Return:** JNJ's cumulative return is 59.05% compared to the S&P 500 (VOO) at 100.88%.
*   **Divergence:** JNJ is currently underperforming the S&P 500 by -41.83%. The relative divergence of 28.9 indicates the current divergence is closer to the minimum divergence seen over the past data period.

*   **Alpha/Beta Analysis:**

| Year       | CAGR    | MDD    | Alpha    | Beta   | Cap(B)  |
| :----------- | :------ | :------- | :------- | :----- | :------ |
| 2015-2017  | 26.0%  | 66.8%  | -2.0%  | -0.1   | 338.9  |
| 2016-2018  | 14.0%  | 10.7%  | -1.0%  | 0.1    | 313.0  |
| 2017-2019  | 20.0%  | 71.5%  | -2.0%  | 0.4    | 353.9  |
| 2018-2020  | 19.0%  | 79.2%  | -4.0%  | 0.4    | 381.8  |
| 2019-2021  | 33.0%  | 79.2%  | -14.0% | 0.5    | 415.0  |
| 2020-2022  | 8.0%   | 79.6%  | 9.0%   | 0.4    | 428.5  |
| 2021-2023  | -19.0% | 79.6%  | -20.0% | 0.3    | 380.2  |
| 2022-2024  | -32.0% | 79.6%  | -53.0% | 0.3    | 350.8  |
| 2023-2025  | 30.0%  | 79.6%  | -35.0% | 0.1    | 500.6  |

*   **Analysis:** The Alpha is mostly negative, indicating JNJ has generally underperformed the S&P 500 on a risk-adjusted basis, except in 2020-2022. The Beta values are generally low (between -0.1 to 0.5), suggesting the stock is less volatile than the market. The Capitalization has grown substantially over the years, reflecting the company's overall growth, although it's recently seen some fluctuation. The maximum drawdown (MDD) is significantly large for a relatively stable company. The CAGR varies wildly.

**2) Recent Stock Price Fluctuations**

*   **Current Price:** 206.37
*   **Last Market Data:** Price: 207.78, Previous Close: 205.78, Change: 0.97
*   **Moving Averages:**
    *   5-day SMA: 209.70
    *   20-day SMA: 206.46
    *   60-day SMA: 195.83

*   **Analysis:** The current price is below the 5-day SMA, near the 20-day SMA, and above the 60-day SMA.  This suggests that the stock is in a short-term downtrend (below 5-day SMA), but a longer-term uptrend (above 60-day SMA). The slight increase in the 'last market' data suggests a potential slight upward momentum.

**3) RSI, PPO, & Hybrid Signal Analysis**

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment Recommended)
*   **RSI:** 53.23 (Neutral - neither overbought nor oversold)
*   **PPO:** -0.19 (Slightly bearish - price slightly below its moving average)
*   **Hybrid Signal:** Cash_0%_Buy 90% of cash (1 shares - Safe - MRI:0.80) (Cash Ratio: 0% on 2025-12-03)
*   **Recent Divergence Change:** -5.1 (Indicates a short-term decline in relative performance compared to the S&P 500)
*   **Expected Return:** -59.0% (Significant underperformance expected relative to the S&P 500 over the long term)

*   **Analysis:** The MRI suggests a medium level of risk, which is reasonable. The RSI and PPO provide a mixed picture, with the RSI being neutral and the PPO slightly bearish. The hybrid signal is suggesting a buy signal, though it also identifies it as a safe play, indicating a low volatility and low return play. The expected return is quite negative, warning caution for long-term investments.

**4) Recent News & Significant Events**

*   **Key Headlines:**
    *   Talc verdict, drug-price pressure, and Q4 earnings in focus.
    *   Stock drops despite market gains.
    *   February 2026 options now available.
    *   Shares surging this month (from November).
    *   Institutional investor increases stake.
    *   Stock trading above 50- & 200-Day SMA.

*   **Analysis:** The news provides a mixed picture. The talc verdict and drug-price pressure are potential headwinds. The stock drop despite market gains is concerning. The availability of options indicates market activity and speculation. The surge in November and the positive SMA positioning from December suggest some positive momentum. The institutional buying reinforces the stock might be a good investment.

**4-2) Analyst Opinions**

*   **Consensus:** Buy (Mean: 2.16)
*   **Target Price:** Average: 209.29, High: 240.00, Low: 155.00

*   **Analysis:** The analyst consensus is a "Buy," and the average target price is slightly above the current price, indicating potential upside. However, the wide range between the high and low target prices suggests uncertainty among analysts.

**5) Recent Earnings Analysis**

| 날짜       | EPS  | 매출       |
| :--------- | :----- | :--------- |
| 2025-10-22 | 2.14 | 23.99 B$   |
| 2025-07-24 | 2.3  | 23.74 B$   |
| 2025-04-23 | 4.57 | 21.89 B$   |
| 2024-10-23 | 1.12 | 22.47 B$   |
| 2025-10-22 | 1.12 | 22.47 B$   |

*   **Analysis:** Revenue has generally been increasing over the past year, but the EPS has been more volatile. The 2025-04-23 number is significant due to the large EPS of 4.57, but it seems abnormal.

**6) Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue     | Profit Margin |
| :----------- | :---------- | :------------- |
| 2025-09-30 | $23.99B    | 69.56%        |
| 2025-06-30 | $23.74B    | 67.87%        |
| 2025-03-31 | $21.89B    | 66.40%        |
| 2024-12-31 | $22.52B    | 68.35%        |
| 2024-09-30 | $22.47B    | 69.01%        |

**Capital and Profitability:**

| Quarter      | Equity      | ROE     |
| :----------- | :---------- | :------ |
| 2025-09-30 | $79.28B    | 6.50%   |
| 2025-06-30 | $78.47B    | 7.06%   |
| 2025-03-31 | $78.11B    | 14.08%  |
| 2024-12-31 | $71.49B    | 4.80%   |
| 2024-09-30 | $70.16B    | 3.84%   |

*   **Analysis:** The company is showing steady revenue growth and very healthy profit margins. Equity has been increasing over the past year. ROE has fluctuated, with the 2025-03-31 quarter being an outlier, but is generally positive, indicating profitability.

**7) Comprehensive Analysis (Summary)**

*   **Overall Assessment:** Johnson & Johnson presents a mixed investment picture.

*   **Positive Signals:**
    *   Solid revenue growth and high profit margins.
    *   Increasing equity.
    *   Analyst consensus is "Buy."
    *   Recent news indicates institutional buying and stock trading above key moving averages.
    *   MRI indicates medium investment recommended

*   **Negative Signals:**
    *   Underperformance compared to the S&P 500.
    *   Mostly negative Alpha values.
    *   Talc verdict and drug-price pressure concerns.
    *   Recent divergence change indicates short-term underperformance.
    *   Negative long-term expected return relative to the S&P 500
    *   High Maximum Drawdown

*   **Key Considerations:**
    *   The significant underperformance compared to the S&P 500 and the negative expected return are major concerns. An investor should carefully consider *why* JNJ is underperforming. Is it sector-specific, company-specific, or a temporary situation?
    *   The talc verdict and drug-price pressure issues should be investigated further to understand their potential long-term impact.
    *   The high profit margins and relatively low Beta values may make JNJ a defensive investment during market downturns, but it may not offer the same upside potential as other growth-oriented stocks.
    *   JNJ's large MDD should be noted and taken into account when making an investment.

*   **Conclusion:** Based on the data provided, JNJ is a hold. Further due diligence is warranted, especially regarding the reasons for the negative expected return relative to the S&P 500.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.